- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The Health Service Products (Provision and Disclosure of Information) Regulations 2018, Section 29.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
29.—(1) This regulation applies where a designated producer of a notifiable presentation—
(a)intends to discontinue the manufacturing or supply of the presentation and considers that this is likely to have a direct impact on any patient who takes, or may need to take, the presentation for the prevention or treatment of a physical or mental illness, or
(b)considers there is likely to be a supply shortage of the presentation which will have a direct impact on any patient who takes, or may need to take, the presentation for the prevention or treatment of a physical or mental illness.
(2) Where this regulation applies, the designated producer must provide the following information to the Secretary of State—
(a)the name of the presentation,
(b)the licensed uses of the presentation which the producer is aware of,
(c)the unlicensed uses of the presentation which the producer is aware of,
(d)the reasons for which the manufacturing or supply is to be discontinued or, as the case may be, the producer considers there is likely to be a supply shortage,
(e)the quantity of the presentation which the producer has available for supply,
(f)where the producer considers there is likely to be a supply shortage—
(i)the anticipated duration of the shortage;
(ii)any steps taken by the producer to address it,
(g)the producer's estimated share of the market,
(h)whether the presentation is made available under an NHS framework contract, and
(i)the name and contact details of a representative of the producer.
(3) The information must be provided—
(a)where the producer intends to discontinue the manufacturing or supply of the relevant presentation—
(i)at least six months before the day on which the manufacturing or supply will cease, or
(ii)where the decision to discontinue the manufacturing or supply is made less than six months before the day on which manufacturing or supply will cease, as soon as reasonably practicable after the producer makes the decision;
(b)where the producer considers there may be a supply shortage of the relevant presentation—
(i)at least six months before any anticipated impact on any patient who takes the presentation is realised, or
(ii)where the producer becomes aware of the likely supply shortage less than six months before the producer considers any anticipated impact will be realised, as soon as reasonably practicable after the producer becomes aware that there may be a supply shortage.
(4) In this regulation—
“notifiable presentation” means a presentation of health service medicine in respect of which a [F1UK] marketing authorisation has been granted F2...
“designated producer”, in relation to a notifiable presentation, means—
the UK producer who holds the [F3UK] marketing authorisation for the presentation, if that producer manufactures the presentation;
otherwise, a UK producer who manufactures the presentation or imports the presentation and supplies it by way of sale;
“ [F4UK] marketing authorisation” has the meaning given in regulation 8(1) of the 2012 Regulations.
Textual Amendments
F1Word in reg. 29(4) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 8 para. 15(a)(i); 2020 c. 1, Sch. 5 para. 1(1)
F2Words in reg. 29(4) omitted (31.12.2020) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 8 para. 15(a)(ii); 2020 c. 1, Sch. 5 para. 1(1)
F3Word in reg. 29(4) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 8 para. 15(b); 2020 c. 1, Sch. 5 para. 1(1)
F4Word in reg. 29(4) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 8 para. 15(c); 2020 c. 1, Sch. 5 para. 1(1)
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: